<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364760">
  <stage>Registered</stage>
  <submitdate>11/08/2013</submitdate>
  <approvaldate>15/08/2013</approvaldate>
  <actrnumber>ACTRN12613000910707</actrnumber>
  <trial_identification>
    <studytitle>Effect of sustained release baclofen on alleviation of gastro-esophageal reflux disease symptoms</studytitle>
    <scientifictitle>Effect of Baclofen sustained release vs placebo on alleviation of reflux symptoms in patients with Gastroesophageal reflux disease  </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastroesophageal reflux disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Addition of oral tablet baclofen sustained release 10 mg twice daily or placebo twice daily for 1 months to the selective treatment of Gastroesophageal reflux disease in Iranian clinics(oral omeprazole 20 mg/d for 2 months). Baclofen/placebo and omeprazole will be start at the same time.
Adherence monitoring by pill count</interventions>
    <comparator>placebo contains microcellulose tablet</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>alleviation of gastroesophagear reflux disesase symptoms by Mayo Gastro-esophageal Reflux questionnaire</outcome>
      <timepoint>1 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>alleviation of quality of life by SF-36 Quality of Life Questionnaire</outcome>
      <timepoint>1 month</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients with diagnosis of Gastroesophageal reflux disease on the basis of Rome 3 criteria
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.history of Hypersensivity to baclofen
2.renal or hepatic failure
3.Neurological diseases
4.pregnant women
5.breastfeeding women
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>14/01/2013</anticipatedstartdate>
    <actualstartdate>14/06/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>10/01/2014</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Tehran</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Shahid Beheshti University of Medical Sciences</primarysponsorname>
    <primarysponsoraddress>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran PO box: 14397-65461 </primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shahid Beheshti University of Medical Sciences</fundingname>
      <fundingaddress>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran PO box: 14397-65461 </fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Proton Pump Inhibitors(PPIs) such as omeprazole are primary treatment for gastroesophageal reflux disease(GERD). Some patients do not cure adequetly with using PPIs. So we want to try effect of addition baclofen sustained release 10 mg twice daily vs placebo in addition to omeprazole 20 mg/d in both groups in alleviation of gastroesophageal reflux symptoms.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics commiittee, Shahid Beheshti University of Medical sciences </ethicname>
      <ethicaddress>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran PO box: 14397-65462</ethicaddress>
      <ethicapprovaldate>1/03/2013</ethicapprovaldate>
      <hrec>576-98234</hrec>
      <ethicsubmitdate>8/02/2013</ethicsubmitdate>
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Mohammad Abbasinazari</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran, Shahid Beheshti University of Medical Sciences PO box: 14397-65461 </address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mohammad Abbasinazari</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran, Shahid Beheshti University of Medical Sciences PO box: 14397-65461 </address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mohammad Abbasinazari</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran, Shahid Beheshti University of Medical Sciences  PO box: 14397-65461 </address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mohammad Abbasinazari</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran PO box: 14397-65461 </address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>